Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.

被引：2
|
作者：
Kawamoto, Yasuyuki
Meguro, Takashi
Yuki, Satoshi
Nakatsumi, Hiroshi
Sasaki, Takahide
Hatanaka, Kazuteru
Uebayashi, Minoru
Iwanaga, Ichiro
Abe, Nobuhiko
Nakamura, Michio
Okuda, Hiroyuki
Eto, Kazunori
Oba, Ayane
Abe, Masakazu
Oba, Koji
Satoh, Taroh
Sakata, Yuh
Sakamoto, Naoya
Komatsu, Yoshito
机构：
[1] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan
[2] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan
[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan
[4] Hokkaido Gastroenterol Hosp, Dept Intenal Med, Sapporo, Hokkaido, Japan
[5] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan
[6] Japanese Red Cross Kitami Hosp, Dept Gastroenterol, Kitami, Hokkaido, Japan
[7] Japanese Red Cross Kitami Hosp, Dept Med Oncol, Kitami, Hokkaido, Japan
[8] Abashiri Kosei Gen Hosp, Dept Gastroenterol, Abashiri, Japan
[9] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[10] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[11] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan
[12] Iwamizawa Municipal Gen Hosp, Dept Gastroenterol, Iwamizawa, Japan
[13] Sapporo Kosei Gen Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan
[14] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan
[15] Univ Tokyo, Interfac Initiat Informat Studies, Tokyo, Japan
[16] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan
[17] Misawa City Hosp, Misawa, Japan
[18] Hokkaido Univ Hosp, Ctr Canc, Sapporo, Hokkaido, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102)
    Nishikawa, Kazuhiro
    Takahashi, Tsunehiro
    Takaishi, Hiromasa
    Miki, Akira
    Noshiro, Hirokazu
    Yoshikawa, Takaki
    Nishida, Yasunori
    Iwasa, Satoru
    Miwa, Hiroto
    Masuishi, Toshiki
    Boku, Narikazu
    Yamada, Yasuhide
    Kodera, Yasuhiro
    Yoshida, Kazuhiro
    Morita, Satoshi
    Sakamoto, Junichi
    Saji, Shigetoyo
    Kitagawa, Yuko
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (01) : 188 - 196
  • [22] Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Li, Chunze
    Wang, Bei
    Chen, Shang-Chiung
    Wada, Russell
    Lu, Dan
    Wang, Xin
    Polhamus, Daniel
    French, Jonathan
    Vadhavkar, Shweta
    Strasak, Alexander
    Smitt, Melanie
    Joshi, Amita
    Samant, Meghna
    Quartino, Angelica
    Jin, Jin
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1079 - 1090
  • [23] A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results
    Kawada, Junji
    Sakai, Daisuke
    Kimura, Yutaka
    Hirao, Motohiro
    Nishikawa, Kazuhiro
    Sugimoto, Naotoshi
    Oka, Yoshio
    Endo, Shunji
    Isozaki, Yutaka
    Matsuyama, Jin
    Kawabata, Ryohei
    Kawase, Tomono
    Fujitani, Kazumasa
    Kurokawa, Yukinori
    Kawakami, Hisato
    Shimokawa, Toshio
    Satoh, Taroh
    ANTICANCER RESEARCH, 2025, 45 (03) : 1077 - 1085
  • [24] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [25] Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102).
    Iwasa, Satoru
    Nishikawa, Kazuhiro
    Miki, Akira
    Noshiro, Hirokazu
    Tsuburaya, Akira
    Nishida, Yasunori
    Miwa, Hiroto
    Masuishi, Toshiki
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Boku, Narikazu
    Yamada, Yasuhide
    Morita, Satoshi
    Sakamoto, Junichi
    Saji, Shigetoyo
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Trastuzumab in HER2-Positive Metastatic Gastric Cancer Profile Report
    Croxtall, Jamie D.
    McKeage, Kate
    BIODRUGS, 2011, 25 (04) : 257 - 259
  • [27] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Al Rabadi, Luai S.
    Cook, Madeline M.
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi, I
    BMC CANCER, 2021, 21 (01)
  • [28] Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
    Luai S. Al Rabadi
    Madeline M. Cook
    Andy J. Kaempf
    Megan M. Saraceni
    Michael A. Savin
    Zahi I. Mitri
    BMC Cancer, 21
  • [29] Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    Park, Ji Soo
    Youn, Jong-Chan
    Shim, Chi Young
    Hong, Geu-Ru
    Lee, Choong-Kun
    Kim, Jee Hyung
    Park, Hyung Soon
    Heo, Su Jin
    Beom, Seung Hoon
    Kim, Hyo Song
    Rha, Sun Young
    Chung, Hyun Cheol
    Kang, Seok-Min
    Jung, Minkyu
    ONCOTARGET, 2017, 8 (37) : 61837 - 61845
  • [30] Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
    Mondaca, Sebastian
    Margolis, Matthew
    Sanchez-Vega, Francisco
    Jonsson, Philip
    Riches, Jamie C.
    Ku, Geoffrey Y.
    Hechtman, Jaclyn F.
    Tuvy, Yaelle
    Berger, Michael F.
    Shah, Manish A.
    Kelsen, David P.
    Ilson, David H.
    Yu, Kenneth
    Goldberg, Zoe
    Epstein, Andrew S.
    Desai, Avni
    Chung, Vincent
    Chou, Joanne F.
    Capanu, Marinela
    Solit, David B.
    Schultz, Nikolaus
    Janjigian, Yelena Y.
    GASTRIC CANCER, 2019, 22 (02) : 355 - 362
12345